Radiomics Markers to Predict Sepsis Induced Acute Respiratory Distress Syndrome

Sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04541264
Collaborator
(none)
300
1
31
9.7

Study Details

Study Description

Brief Summary

Introduction:

Sepsis-induced acute respiratory distress syndrome(SI-ARDS) is a common complication of severe sepsis and is an independent contributor to poor prognosis of patients. It remains a clinical challenge to identify the SI-ARDS early and accurately, which could optimize the treatment strategy and reduce the mortality risk. Radiomics high-dimensional features extracted from CT images offer an insight into microvascular damage of SI-ARDS that are imperceptible to human eyes and aspects of intra-alveolar heterogeneity with potential prognostic relevance.

Methods:

Study design Investigators screened all patients with sepsis and septic shock who are treated in Sun Yat-sen Memorial Hospital, Sun Yat-sen University during the period from 1 May 2015 and 30 May 2022. Patients were recruited retrospectively from May 2015 to April 2021 as discovering group, and prospectively during the period from May 2021 to May 2022 as validation group. Follow-up will conducted until April 2023.

Cohort descriptions and definitions Investigators plan to recruit 160 patients in discovering group, 40 patients in internal validation group, and 100 patients in external validation group. Patients between 18 and 80 years of age with sepsis and septic shock will be screened for eligibility. SI-ARDS is defined by sequential occurrence of the sepsis-3 consensus criteria for sepsis and the Berlin Definition for ARDS. The exclusion criteria are:

  1. admission stay <24hours,

  2. the presence of end-stage lung disease or long-term oxygen therapy,

  3. critically ill patients who have started mechanical ventilation caused by SI-ARDS before admission,

  4. a history of lung transplantation and chronic obstructive pulmonary disease,

  5. cancer patients not/have received chemotherapy.

Outcome measures In this study, the primary outcome measure was the occurrence rates of acute respiratory distress syndrome(ARDS). It refers to the occurrence of sepsis patients progressed into ARDS.

Secondary outcome measures were as follows:

1.28-day mortality 2.ventilator-free days 3.respiratory failure-free days

Data collection All clinical data were collected by investigators and trained personnel. Each participant's data will be filled in electronic case report forms (CRF) and store online using REDCap (Research Electronic Data Capture).

Discussion:

SI-ARDS is one common severe complication with critically ill sepsis patients, which causes high mortality and poor prognosis. Early ARDS patient(arterial oxygen tension/inspired oxygen fraction [PaO2/FIO2] ≤ 300 mmHg but > 200 mmHg) may not require invasive mechanical ventilation, and is more readily reversible than acute respiratory distress syndrome(ARDS). In this ambispecive cohort study, investigators developed and validated novel nomograms incorporating the radiomics signature and clinical signature to provide an easy-to-use and individualized prediction of SI-ARDS occurrence and severe degree in patients with early stage.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: radiomic of chest CT

Study Design

Study Type:
Observational
Anticipated Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Other
Official Title:
Application of Radiomics as Predicted Marker for Patients With Sepsis Induced Acute Respiratory Distress Syndrome:a Protocol for an Observational Ambispective Cohort Study
Actual Study Start Date :
Jun 1, 2021
Anticipated Primary Completion Date :
Aug 17, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Model reconstruction cohort

160 patients were recruited retrospectively from May 2015 to April 2020 as discovering group.

Diagnostic Test: radiomic of chest CT
radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.

Internal validation cohort

40 patients were recruited retrospectively from May 2015 to April 2020 as internal validation group.

Diagnostic Test: radiomic of chest CT
radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.

External validation cohort

100 patients will be recruited prospectively during the period from May 2020 to April 2021 as external validation group.

Diagnostic Test: radiomic of chest CT
radiomics as a quantitative imaging method for early detection, risk assessment, and treatment decisions for early predicting sepsis induced acute respiratory distress syndrome.

Outcome Measures

Primary Outcome Measures

  1. occurrence rates of acute respiratory distress syndrome(ARDS) [from date of admission until the date of disease progressing to ARDS, assessed up to 28days]

    It refers to the occurrence of sepsis patients progressed into ARDS in all patients enrolled into the study

Secondary Outcome Measures

  1. 28-day mortality [from date of admission until the date of death from any cause, assessed up to 28days]

    a cox proportion hazards regression model was used to analysis the survival outcome of patients with sepsis within 28 days according to radiomics characteristics

  2. ventilator-free days [from date of admission until the date of ventilation or discharge from hospital, assessed up to 28days]

    defined as the number of calendar days after initiating ventilator unassisted breathing to day 28 after admission

  3. respiratory failure-free days [from date of admission until the initiating date of respiratory failure, assessed up to 28days]

    defined as the day without evidence of non-respiratory organ failure

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinical diagnosis of sepsis

  • Clinical diagnosis of ARDS

  • Written informed consent in external validation cohort

Exclusion Criteria:
  • admission stay <24hours,

  • the presence of end-stage lung disease or long-term oxygen therapy,

  • critically ill patients who have started mechanical ventilation caused by SA-ARDS before admission,

  • a history of lung transplantation and chronic obstructive pulmonary disease,

  • cancer patients not/have received chemotherapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Sun Yat-sen Memorial Hospital, Sun Yat-sen University Guangzhou Guangdong China 510000

Sponsors and Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Li Li, associate chief physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
ClinicalTrials.gov Identifier:
NCT04541264
Other Study ID Numbers:
  • SYSEC-KY-KS-2020-122
First Posted:
Sep 9, 2020
Last Update Posted:
Jun 18, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Li Li, associate chief physician, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 18, 2021